Herpes virus

Long COVID could be caused by the virus lingering in the body. Here's what the science says

Retrieved on: 
Saturday, June 10, 2023
Inflammation, Infection, Tissue, Heart, Epstein–Barr virus, DNA, Autoantibody, HIV, Vaccination, SARS-CoV-2, Eye, Herve Bostan Amani, Viral, Brain, COVID, Cell, RNA, Antibody, Autoimmunity, HERV, Psoriasis, Thought, Measles, Inflammatory bowel disease, Nose, Viral disease, Herpes virus, Dementia, Protein, Patient, Risk, Infectious mononucleosis, Blood, Immune system, Conditional sentence, Colonoscopy, DSM-IV codes, Autoimmune disease, Area studies, Research, Virus, Autopsy, Fatigue, Pharmaceutical industry, Vaccine, Copper

When symptoms last longer than 12 weeks, the condition is known as long COVID.

Key Points: 
  • When symptoms last longer than 12 weeks, the condition is known as long COVID.
  • Long COVID encompasses up to 200 different symptoms.
  • One factor that may be associated with long COVID is that the virus hasn’t fully cleared from the body after the initial infection.

Other viruses lurk in the body

    • This means the virus conceals itself within cells and remains dormant.
    • HIV, in particular, can remain dormant in infected cells throughout the body.
    • Several studies have shown COVID can also reactivate the Epstein-Barr virus, which has remained in the body in a latent state.

How do we know COVID stays in the body?

    • SARS-CoV-2 RNA was detected in at least half the samples of heart, lymph glands, eye, nerve, brain and lung tissue tested.
    • These patients had asymptomatic COVID and were PCR-negative from swabs of the nose and throat at four months.
    • Initial studies did not always suggest a strong relationship between the long-term detection of SARS-CoV-2 and long COVID symptoms.

How might the delay in clearing the virus impact people with long COVID?

    • We have previously shown immune dysfunction and inflammation persist up to eight months in people with long COVID that initially had mild to moderate disease.
    • Read more:
      When does COVID become long COVID?
    • Antibodies reactive to Epstein-Barr virus are elevated in people with long COVID suggesting Epstein-Barr virus reactivation, likely through activating the immune system.
    • This should include examination of viral RNA and protein in both blood and tissues in people with long COVID independent of disease severity.

DGAP-News: AiCuris nominates team of researchers from the Universitätsklinikum Erlangen as one of the 2022 winners of AiCubator Resident Status, a corporate innovation accelerator initiative

Retrieved on: 
Thursday, September 8, 2022
MSD, HCMV, Spleen, Drug of last resort, Medical Center, CEO, Hematopoietic stem cell transplantation, Interest, Program, HBV, Research, Hepatitis B virus, Liver, Therapy, Herpes virus, Virus, BK virus, Infection, Pritelivir, Standard of care, Stillbirth, HSV, AMR, Simplex, Company, NEC Laboratories America, BKV, BK, Huber loss, NEC, Transgender hormone therapy, CMV, Sepsis, Institute, Drug development, Industry, Virology, Interior design, Security (finance), Pharmaceutical industry, Vaccine, EU, Bayer

AiCuris nominates team of researchers from the Universittsklinikum Erlangen as one of the 2022 winners of AiCubator Resident Status, a corporate innovation accelerator initiative

Key Points: 
  • AiCuris nominates team of researchers from the Universittsklinikum Erlangen as one of the 2022 winners of AiCubator Resident Status, a corporate innovation accelerator initiative
    The issuer is solely responsible for the content of this announcement.
  • We are excited to welcome Prof. Dr. Manfred Marschall and his team as one of the winners of the AiCubator Resident Status in 2022, said Dr. Holger Zimmermann, CEO of AiCuris Anti-infective Cures AG.
  • We are very much looking forward to working with the winning team and supporting them to advance their promising project to the next level.
  • We appreciate and feel honored that our project has been selected for the AiCubator program, said Prof. Dr. Manfred Marschall.

Rational Vaccines names Dr. Konstantin Kousoulas Vice President of Scientific Affairs

Retrieved on: 
Friday, February 26, 2021
Medical specialties, Virology, Viral diseases, Sexually transmitted diseases and infections, Microbiology, Herpes, Biology of bipolar disorder, Herpes simplex, HSV-2, Herpes virus, Herpesviridae, Vaccine

CAMBRIDGE, Mass., Feb. 26, 2021 /PRNewswire/ --Leading virologist Konstantin "Gus" Kousoulas joined Rational Vaccines as vice president of Scientific Affairs where he will work to further the company's core mission of eradicating the world of the herpes simplex virus (HSV), the company announced today.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 26, 2021 /PRNewswire/ --Leading virologist Konstantin "Gus" Kousoulas joined Rational Vaccines as vice president of Scientific Affairs where he will work to further the company's core mission of eradicating the world of the herpes simplex virus (HSV), the company announced today.
  • His addition to the team brings us one step closer to our goal of eradicating the Herpes pandemic."
  • Kousoulas' research focuses primarily on the molecular biology and the immunopathogenesis of human herpes viruses.
  • Rational Vaccines develops rationally engineered, live attenuated viral immunotherapeutic and prophylactic vaccine candidates, particularly focused on combating all diseases resulting from herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections.

Herpesviruses Hedge Their Bets to Optimize Survival

Retrieved on: 
Monday, July 6, 2020
Viruses, Branches of biology, Viral diseases, Microbiology, Betaherpesvirinae, Infectious causes of cancer, Animal virology, Herpesviridae, Dormancy, Organ transplantation, Herpes virus, Cytomegalovirus

However, in some the virus emerges from dormancy; for example in babies and in transplant recipients, and it causes serious problems and even death.

Key Points: 
  • However, in some the virus emerges from dormancy; for example in babies and in transplant recipients, and it causes serious problems and even death.
  • Indeed, cytomegalovirus is the leading cause of birth defects and the leading cause of transplant failures.
  • Although there were established examples of plants "hedging their bets" by producing a variety of seeds that can survive in different conditions, the work was the first example of a virus using latency to hedge bets.
  • "We'd like to see if our new findings could lead to new approaches to treating latent herpesviruses," says Chaturvedi.